News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

New Hydrogel From the Institute of Bioengineering and Nanotechnology and IBM Corporation (IBM) Destroys Superbugs and Drug-Resistant Biofilms



1/24/2013 9:22:37 AM

Singapore, January 24, 2013 – Researchers from the Institute of Bioengineering and Nanotechnology (IBN) and IBM Research today unveiled the first-ever antimicrobial hydrogel that can break apart biofilms and destroy multidrug-resistant superbugs upon contact. Tests have demonstrated the effectiveness of this novel synthetic material in eliminating various types of bacteria and fungi that are leading causes of microbial infections, and preventing them from developing antibiotic resistance. This discovery may be used in wound healing, medical device and contact lens coating, skin infection treatment and dental fillings.

IBN Executive Director Professor Jackie Y. Ying said, “As a multidisciplinary research institute, IBN believes that effective solutions for complex healthcare problems can only emerge when different fields of expertise come together. Our longstanding partnership with IBM reflects the collaborative creativity across multiple platforms that we aim to foster with leading institutions and organizations. By combining IBN’s biomaterials expertise and IBM’s experience in polymer chemistry, we were able to pioneer the development of a new nanomaterial that can improve medical treatment and help to save lives.”

Dr Yi-Yan Yang, Group Leader at IBN said, “The mutations of bacteria and fungi, and misuse of antibiotics have complicated the treatment of microbial infections in recent years. Our lab is focused on developing effective antimicrobial therapy using inexpensive, biodegradable and biocompatible polymer material. With this new advance, we are able to target the most common and challenging bacterial and fungal diseases, and adapt our polymers for a broad range of applications to combat microbial infections.”

More than 80% of all human microbial infections are related to biofilm. This is particularly challenging for infections associated with the use of medical equipment and devices. Biofilms are microbial cells that can easily colonize on almost any tissue or surface. They contribute significantly to hospital-acquired infections, which are among the top five leading causes of death in the United States and account for US$11 billion in healthcare spending each year.

In Singapore, antimicrobial drug resistance is a major healthcare problem because of the extensive use of antibiotics and medical equipment such as intravascular catheters and orthopedic implants in patients. Once in the body, these instruments become potential breeding grounds for bacterial growth. This provides a continuous source of contamination, which could result in prolonged hospitalization, higher medical costs, and greater risk of death. Research has shown that patients in Singapore with microbial infections were 10.2 times more likely to die during their hospitalization, had 4.6 times longer hospitalization, and incurred 4 times higher hospitalization cost compared to patients with no infections. The emergence of new strains of superbugs and shortage of new drugs has exacerbated the need for an effective antimicrobial solution. Traditional household antiseptics and disinfectants are also proving to be ineffective in eliminating drug-resistant germs.

Under Dr Yang, IBN's Nanomedicine group has been conducting research on polymer and peptide nanoparticles as antimicrobial agents since 2007. Her lab has published 15 papers in high-impact factor journals such as Nature Nanotechnology, Nature Chemistry, Nano Today, Advanced Materials, ACS Nano, Biomaterials, and SMALL and filed 10 patents on their antimicrobial technologies.

Recently, Dr Yang’s group and their collaborators from IBM Research co-developed a synthetic gel that is biodegradable, biocompatible and cost-effective. With over 90% water content, the hydrogel is highly flexible and easy to adapt for different uses. This gel can target the bacteria and fungi behind seven of the most common hospital-acquired infections such as MRSA (methicillin-resistant Staphylococcus aureus), VRE (vancomycin-resistant enterococcus), multidrug-resistant Acinetobacter baumanniiand Klebsiella pneumoniae, E. coli, Candida albicans and Cryptococcus neoformans fungi.

This new gel is comprised of the novel polymer material jointly developed by IBN and IBM Research in 2010. When mixed with water and heated to body temperature, the polymers form spontaneously into a moldable gel, due to the self-associative interactions between the polymer molecules. This allows the hydrogel to target multidrug-resistant biofilms at various parts of the body and surfaces without being flushed away. Once the antimicrobial function is activated and performed, the biodegradable gel can be naturally eliminated by the body.

Using the new polymer material as a basic building block, IBN can now provide a comprehensive antimicrobial solution to combat drug-resistant bacteria and fungi for a range of medical and consumer products.

“Bacterial biofilms are a serious health threat and the ability to disperse such films is critical. The soft consistency of our non-toxic materials makes them ideal for injectable and topical applications as well as coatings and lubricants for medical devices such as catheters,” said Dr James Hedrick, Advanced Organic Materials Scientist, IBM Research. “Whether it’s designing degradable materials to eliminate polymers occupying landfills or new antimicrobial hydrogels that don’t have drug resistance, our partnership with IBN has allowed us to take what the industry has deemed really important and create solutions that are applicable to many technologies in medicine.”

This latest research breakthrough was recently published in the leading peer-reviewed journal, Angewandte Chemie International Edition.

This research is funded by the Institute of Bioengineering and Nanotechnology. ETPL, the technology transfer arm of the Agency for Science, Technology and Research, funded the skin biocompatibility testing of the antimicrobial hydrogel for its commercial development for consumer care.

References:

1. “Y. Li, K. Fukushima, D. J. Coady, A. C. Engler, S. Liu, Y. Huang, J. S. Cho, Y. Guo, L. S. Miller, J. P. K. Tan, P. L. R. Ee, W. Fan, Y. Y. Yang, and J. L. Hedrick, “Broad-Spectrum Antimicrobial and Biofilm-Disrupting Hydrogels: Stereocomplex-Driven Supramolecular Assemblies,” Angewandte Chemie International Edition, 135 (2013) 702-706.

2. “S. Q. Liu, C. Yang, Y. Huang, X. Ding, Y. Li, W. M. Fan, J. L. Hedrick and Y. Y. Yang, “Antimicrobial and Antifouling Hydrogels Formed In Situ from Polycarbonate and Poly(ethylene glycol) via Michael Addition,“ Advanced Materials, 24 (2012) 6484-6489.

3. X. Ding, C. Yang, T. P. Lim, L. Y. Hsu, A. C. Engler, J. L. Hedrick and Y. Y Yang, “Antibacterial and Antifouling Catheter Coatings Using Surface Grafted PEG-b-Cationic Polycarbonate Diblock Copolymers,” Biomaterials, 33 (2012) 6593-6603.

For interviews, queries and photo requests, please contact:

Elena Tan

Phone: 65 6824 7032

Email: elenatan@ibn.a-star.edu.sg

Nidyah Sani

Phone: 65 6824 7005

Email: nidyah@ibn.a-star.edu.sg

About the Institute of Bioengineering and Nanotechnology

The Institute of Bioengineering and Nanotechnology (IBN) was established in 2003 and is spearheaded by its Executive Director, Professor Jackie Yi-Ru Ying.

Professor Ying was a Professor of Chemical Engineering at the Massachusetts Institute of Technology (1992 - 2005). She was recognized as one of “One Hundred Engineers of the Modern Era” by the American Institute of Chemical Engineers in 2008 for her groundbreaking work on nanostructured systems, nanoporous materials and host matrices for quantum dots and wires.

Under her direction, IBN conducts research at the cutting-edge of bioengineering and nanotechnology. Its programs are geared towards linking multiple disciplines across engineering, science and medicine to produce research breakthroughs that will improve healthcare and our quality of life.

IBN’s research activities are focused in the following areas:

Nanomedicine, where functionalized polymers, hydrogels and biologics are developed as therapeutics and carriers for the controlled release and targeted delivery of therapeutics to diseased cells and organs.

Cell and Tissue Engineering, where biomimicking materials, stem cell technology, microfluidic systems and bioimaging tools are combined to develop novel approaches to regenerative medicine and artificial organs.

Biodevices and Diagnostics, which involve nanotechnology and microfabricated platforms for high-throughput biomarker and drug screening, automated biologics synthesis, and rapid disease diagnosis.

Green Chemistry and Energy, which encompass the green synthesis of chemicals and pharmaceuticals, catalytic conversion of biomass, utilization of carbon dioxide, and new nanocomposite materials for energy applications.

IBN's innovative research is aimed at creating new knowledge and intellectual properties in the emerging fields of bioengineering and nanotechnology to attract top-notch researchers and business partners to Singapore. Since 2003, IBN researchers have published over 820 papers in leading journals.

IBN also plays an active role in technology transfer and spinning off companies, linking the research institute and industrial partners to other global institutions. The Institute has a portfolio of over 581 patents/patent applications, and welcomes industrial and clinical partners to collaborate on and co-develop its technologies. IBN has successfully commercialized 46 patents/patent applications, and has established 6 spin-off companies.

IBN's current staff and students strength stands at over 150 scientists, engineers and medical doctors. With its multinational and multidisciplinary research staff, the institute is geared towards generating new biomaterials, devices, systems and processes to boost Singapore’s economy in the medical technology, pharmaceuticals, chemicals, consumer products and clean technology sectors.

IBN is also committed to nurturing young talents. Besides the training of PhD students, IBN has a Youth Research Program (YRP) for students and teachers from secondary schools, junior colleges, polytechnics, and universities. Since its inception in October 2003, IBN’s YRP has reached out to more than 59,860 students and teachers from 289 local and overseas schools and institutions. Over 1,670 students and teachers have completed research attachments at IBN for a minimum period of four weeks.

www.ibn.a-star.edu.sg


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES